Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

On February 6, 2026, Nature Communications published online a study led by Academician Xu Binghe from the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences. The single-arm Phase Ib trial evaluated the efficacy and safety of the novel oral pan-AKT inhibitor afuresertib combined with fulvestrant in previously treated patients with HR-positive/HER2-negative advanced breast cancer.
CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

With the continuous emergence of novel therapies and landmark clinical evidence, the treatment landscape of urothelial carcinoma is undergoing profound transformation. Ahead of the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, Oncology Frontier – UroStream presents a special series of expert previews on major genitourinary oncology guidelines. In this issue, Professor Cuijian Zhang from Peking University First Hospital, Secretary of the CSCO Urothelial Carcinoma Expert Committee, discusses the evolution of the CSCO urothelial carcinoma guidelines, highlights potential updates in the upcoming edition, and shares insights into the clinical significance of emerging evidence and future directions in the field. His perspectives offer clinicians an early look at evolving treatment paradigms aimed at improving outcomes for Chinese patients.
International Perspectives from EBMT | Professor Florent Malard: New Frontiers in Microbiome-Based Therapy for the Treatment and Prevention of Graft-versus-Host Disease

International Perspectives from EBMT | Professor Florent Malard: New Frontiers in Microbiome-Based Therapy for the Treatment and Prevention of Graft-versus-Host Disease

Graft-versus-host disease (GVHD) remains one of the most severe complications following hematopoietic stem cell transplantation. Among its manifestations, acute gastrointestinal GVHD is particularly challenging to manage. Despite standard therapies, a substantial proportion of patients fail treatment, and no approved therapeutic options currently exist for those with refractory disease, representing a major unmet medical need.
Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

To further promote the expansion, equitable distribution, and accessibility of high-quality cancer care resources, and to enhance the academic and clinical capabilities of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.
Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years of transformation, progressing from “following” to “running alongside,” and now to “leading.”
Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML

Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML

Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from myeloid stem cells, characterized by significant biological diversity and generally poor prognosis. The global disease burden of AML continues to rise, with the age-standardized incidence increasing by 87.3% between 1990 and 2021, underscoring the urgent need for improved therapeutic strategies.
North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?

North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?

In the era of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC), an important clinical question has emerged: is platinum still indispensable? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Jia Wang from Zhongshan Hospital, Dalian University presented an in-depth analysis of this issue. Drawing on treatment goals, mechanistic rationale, clinical evidence, and individualized strategies, she systematically reviewed the role and challenges of platinum agents in neoadjuvant immunotherapy for TNBC and proposed future directions toward precision “de-escalation” therapy.